← Eichor
Condition: Decitabine Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Decitabine

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06379360Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreat
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06827899Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT07101588DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML
Phase 3 · 1 location(s) · The Second Affiliated Hospital of Kunming Medical University · NCT07712848Avapritinib With Decitabine in Patients With SM-AHN
Phase 1 · 7 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06327685Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Phase 1 · 7 location(s) · Syntrix Biosystems, Inc. · NCT04245397Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
Phase 1 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06651866A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Phase 1 · 1 location(s) · EpiDestiny, Inc. · NCT04055818A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine
Phase 2 · 2 location(s) · Franziska Wachter · NCT05796570Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transpla
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06393361Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Phase 2/Phase 3 · 1 location(s) · Peking University People's Hospital · NCT03793517Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06046313Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Ref
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04774393Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant
Phase 2 · 1 location(s) · University of Washington · NCT07148947Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06393985A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Phase 1 · 1 location(s) · Treebough Therapies · NCT07006025A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After
Phase 1 · 8 location(s) · National Cancer Institute (NCI) · NCT07012044Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06454448A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04872543Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Phase 2 · 1 location(s) · Loyola University · NCT05983276Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Phase 1 · 5 location(s) · Clinical Hub for Interventional Research (CHOIR) · NCT05636514Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and
Phase 1 · 1 location(s) · Mayo Clinic · NCT06997094A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activit
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06191978Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01515527Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Ne
Phase 2 · 1 location(s) · University of Washington · NCT04282187FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Montefiore Medical Center · NCT07283094Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Phase 1 · 1 location(s) · David Avigan · NCT07374029Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Phase 2 · 9 location(s) · Bio-Path Holdings, Inc. · NCT02781883
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.